Literature DB >> 17057021

Latent myeloproliferative disorder revealed by the JAK2-V617F mutation and endogenous megakaryocytic colonies in patients with splanchnic vein thrombosis.

Marjorie Boissinot, Eric Lippert, Francois Girodon, Irene Dobo, Marc Fouassier, Claude Masliah, Vincent Praloran, Sylvie Hermouet.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17057021     DOI： 10.1182/blood-2006-05-021527

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  15 in total

1.  Concordance of assays designed for the quantification of JAK2V617F: a multicenter study.

Authors:  Eric Lippert; François Girodon; Emma Hammond; Jaroslav Jelinek; N Scott Reading; Boris Fehse; Katy Hanlon; Mirjam Hermans; Céline Richard; Sabina Swierczek; Valérie Ugo; Serge Carillo; Véronique Harrivel; Christophe Marzac; Daniela Pietra; Marta Sobas; Morgane Mounier; Marina Migeon; Sian Ellard; Nicolaus Kröger; Richard Herrmann; Josef T Prchal; Radek C Skoda; Sylvie Hermouet
Journal:  Haematologica       Date:  2008-11-10       Impact factor: 9.941

2.  Endogenous megakaryocytic colonies underline association between megakaryocytes and calreticulin mutations in essential thrombocythemia.

Authors:  Julie Mondet; Ji-Hye Park; Audrey Menard; Christophe Marzac; Serge Carillo; Emmanuel Pourcelot; Francois Girodon; Xenia Cabagnols; Laurence Lodé; Nuria Socoro; Martine Chauvet; Claude-Eric Bulabois; Pascale Cony-Makhoul; Selim Corm; Jean-Yves Cahn; Pascal Mossuz
Journal:  Haematologica       Date:  2015-02-06       Impact factor: 9.941

Review 3.  Megakaryopoiesis.

Authors:  Amy E Geddis
Journal:  Semin Hematol       Date:  2010-07       Impact factor: 3.851

4.  Polycythemia vera: gender-related phenotypic differences.

Authors:  Raffaele Landolfi; Leonardo Di Gennaro; Maria Anna Nicolazzi; Igor Giarretta; RosaMaria Marfisi; Roberto Marchioli
Journal:  Intern Emerg Med       Date:  2011-06-10       Impact factor: 3.397

5.  JAK2 (V617F) Positive Latent Myeloproliferative Neoplasm Presenting with Splanchnic Vein Thrombosis.

Authors:  Amandeep Salhotra; Thein H Oo
Journal:  Indian J Hematol Blood Transfus       Date:  2012-12-18       Impact factor: 0.900

6.  JAK2V617F mutation in patients with splanchnic vein thrombosis.

Authors:  Sandra Guerra Xavier; Telma Gadelha; Glicínia Pimenta; Angela Maria Eugenio; Daniel Dias Ribeiro; Fernanda Mendes Gomes; Martin Bonamino; Ilana Renault Zalcberg; Nelson Spector
Journal:  Dig Dis Sci       Date:  2009-08-19       Impact factor: 3.199

7.  The clinical significance of JAK2V617F mutation for Philadelphia-negative chronic myeloproliferative neoplasms in patients with splanchnic vein thrombosis.

Authors:  Ipek Yonal; Binnur Pinarbası; Fehmi Hindilerden; Veysel Sabri Hancer; Meliha Nalcaci; Sabahattin Kaymakoglu; Reyhan Diz-Kucukkaya
Journal:  J Thromb Thrombolysis       Date:  2012-10       Impact factor: 2.300

8.  Low burden of a JAK2-V617F mutated clone in monoclonal haematopoiesis in a Japanese woman with Budd-Chiari syndrome.

Authors:  Kohtaro Toyama; Masamitsu Karasawa; Arito Yamane; Hiromi Koiso; Akihiko Yokohama; Hideki Uchiumi; Takayuki Saitoh; Hiroshi Handa; Ken Sato; Hitoshi Takagi; Shuichi Miyawaki; Hirokazu Murakami; Yoshihisa Nojima; Norifumi Tsukamoto
Journal:  Int J Hematol       Date:  2009-03-24       Impact factor: 2.490

9.  JAK2V617F leads to intrinsic changes in platelet formation and reactivity in a knock-in mouse model of essential thrombocythemia.

Authors:  Catherine M Hobbs; Harriet Manning; Cavan Bennett; Louella Vasquez; Sonia Severin; Lauren Brain; Alexandra Mazharian; Jose A Guerrero; Juan Li; Nicole Soranzo; Anthony R Green; Steve P Watson; Cedric Ghevaert
Journal:  Blood       Date:  2013-10-01       Impact factor: 22.113

Review 10.  The diagnosis of BCR/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markers.

Authors:  Torsten Haferlach; Ulrike Bacher; Wolfgang Kern; Susanne Schnittger; Claudia Haferlach
Journal:  Ann Hematol       Date:  2007-10-16       Impact factor: 3.673
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.